Investigational Microbiome Therapeutic SER-109 Reduces Risk for CDI Recurrence
Researchers evaluated the safety of SER-109 and its effect on CDI recurrence among adult outpatients.
Researchers evaluated the safety of SER-109 and its effect on CDI recurrence among adult outpatients.